⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31265934 | 0.79 | GPR84 (0.40) | — | |
| SCHEMBL2116183 | 0.77 | — | — | |
| SCHEMBL4969798 | 0.77 | — | — | |
| SCHEMBL1701047 | 0.72 | — | — | |
| SCHEMBL11598497 | 0.72 | USP2 (0.33) | — | |
| SCHEMBL7145471 | 0.71 | — | — | |
| SCHEMBL5814834 | 0.71 | IDH1 (0.53) | — | |
| SCHEMBL31329400 | 0.70 | ELANE (0.36) | — | |
| SCHEMBL31329433 | 0.70 | ELANE (0.36) | — | |
| SCHEMBL4479222 | 0.70 | NQO1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012570-B2 | Acetate compounds useful as odorants | GIVAUDAN SA (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20240008524-A1 | CONSUMABLE | Nicoventures Trading Limited (GB) | 2024-01-11 | — | — | US | disclosed |
| US-20230337719-A1 | ORAL PRODUCT | NICOVENTURES TRADING LTD (GB) | 2023-10-26 | — | — | US | disclosed |
| EP-4203714-A1 | ORAL PRODUCT | Nicoventures Trading Limited (GB) | 2023-07-05 | — | — | EP | disclosed |
| EP-4203717-A1 | CONSUMABLE | Nicoventures Trading Limited (GB) | 2023-07-05 | — | — | EP | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| US-20220119733-A1 | ACETATE COMPOUNDS USEFUL AS ODORANTS | GIVAUDAN SA (CH) | 2022-04-21 | — | — | US | disclosed |
| WO-2022043700-A1 | ORAL PRODUCT | Nicoventures Trading Limited (GB) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043666-A1 | CONSUMABLE | Nicoventures Trading Limited (GB) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2018049008-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |